How We are Defending and Employing Psilocybin Research and Development

FTO has taken the first step in seeking to invalidate Compass’s bad patents on so-called “Polymorph A”, but the dispute is not over. FTO’s invalidity Petitions are just the first action in a dispute that likely will continue through this year and into the next. The resolution of that dispute will shape the course of psilocybin research and therapy for decades to come.

We’ve challenged Compass’ patents because we believe they will likely impede individuals with treatable disorders from receiving affordable and widely available psilocybin medicines.

If you share FTO’s values, we encourage you to donate to help fund our mission for the benefit of all.